---
{"dg-publish":true,"permalink":"/USMLE/REVIEW/Monoclonal antibodies/","tags":["t1"]}
---

# Oncology

*   **Trastuzumab (Herceptin)**
    *   **Target:** HER2/neu (a receptor tyrosine kinase).
    *   **Use:** HER2-positive breast and gastric cancer.
    *   **Buzzwords/Pearls:** **"Trust-Her-2"** stick together. Significant adverse effect is **cardiotoxicity** (reversible); must check ejection fraction (echocardiogram) before and during treatment.

*   **Rituximab**
    *   **Target:** CD20 antigen on B-cells.
    *   **Use:** B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, ITP.
    *   **Buzzwords/Pearls:** **"Ritu-CD20-mab"** helps remember the target. Causes B-cell depletion. Increased risk of Progressive Multifocal Leukoencephalopathy (PML).

*   **Bevacizumab**
    *   **Target:** VEGF (Vascular Endothelial Growth Factor).
    *   **Use:** Solid tumors (colorectal, lung cancer), wet macular degeneration.
    *   **Buzzwords/Pearls:** Think **"BEV"** for **B**lood **EV**essel inhibitor. Inhibits angiogenesis. Adverse effects include hemorrhage, blood clots, and impaired wound healing.

*   **Cetuximab**
    *   **Target:** EGFR (Epidermal Growth Factor Receptor).
    *   **Use:** Stage IV colorectal cancer (only for *KRAS* wild-type), head and neck cancer.
    *   **Buzzwords/Pearls:** Side effects include an acneiform **rash** (papulopustular) and diarrhea. Think **C**etuximab for **C**olorectal Ca and rash.

*   **Checkpoint Inhibitors (e.g., Pembrolizumab, Nivolumab, Atezolizumab)**
    *   **Target:** PD-1 (on T-cells) or PD-L1 (on tumor cells).
    *   **Use:** Melanoma, lung cancer, and many other solid tumors.
    *   **Buzzwords/Pearls:** "Unleashes" the immune system to attack cancer. Can cause widespread autoimmune side effects (e.g., colitis, pneumonitis, endocrinopathies). Think **"-mab" unleashing "mayhem"** on the tumor by taking the "brakes" off T-cells.

# Immunology/Rheumatology

*   **Infliximab, Adalimumab, Golimumab, Certolizumab**
    *   **Target:** TNF-α.
    *   **Use:** Autoimmune conditions (rheumatoid arthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease).
    *   **Buzzwords/Pearls:** **"TNF-α gets INFLIX-ion"** (inflicts damage). Before starting, must screen for latent TB (PPD or IGRA) as it can cause reactivation.

*   **Eculizumab**
    *   **Target:** Complement protein C5.
    *   **Use:** Paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS).
    *   **Buzzwords/Pearls:** Prevents formation of the MAC (Membrane Attack Complex). Patients require vaccination against *Neisseria meningitidis* due to increased risk of infection.

*   **Ustekinumab**
    *   **Target:** IL-12 and IL-23.
    *   **Use:** Psoriasis, psoriatic arthritis, Crohn's disease.
    *   **Buzzwords/Pearls:** Think **"U-SITE-O-KIN-umab"** for its action on cytokines IL-12/23.

# Cardiology/Hematology

*   **Abciximab**
    *   **Target:** Glycoprotein IIb/IIIa receptor on platelets.
    *   **Use:** Antiplatelet agent for percutaneous coronary intervention (PCI).
    *   **Buzzwords/Pearls:** Think **"ABC-six-imab"** sounds like **"IIb/IIIa-mab"**. Prevents platelet aggregation.

# Other High-Yield Agents

*   **Denosumab**
    *   **Target:** RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand).
    *   **Use:** Osteoporosis (mimics osteoprotegerin), bone metastases.
    *   **Buzzwords/Pearls:** **"Deno-su-mab"** for **Den**sity of b**o**ne.

*   **Omalizumab**
    *   **Target:** IgE.
    *   **Use:** Severe, refractory allergic asthma.
    *   **Buzzwords/Pearls:** Binds free IgE, preventing mast cell activation. Think **"O-my-GEE"** for Ig**E**.

*   **Palivizumab**
    *   **Target:** RSV F-protein (Respiratory Syncytial Virus).
    *   **Use:** RSV prophylaxis for high-risk infants (e.g., premature, chronic lung disease).
    *   **Buzzwords/Pearls:** This is a **p**assive immunization for **p**rophylaxis. Think **"Pali-VIZ-umab"** for R**S**V.